We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Serological Assays Define Extent of Legionnaires’ Disease Outbreak

By LabMedica International staff writers
Posted on 29 Apr 2015
Print article
The DSX Automated System for enzyme-linked immunosorbent assays
The DSX Automated System for enzyme-linked immunosorbent assays (Photo courtesy of Dynex Technologies)
Microbiological diagnosis of Legionnaires’ disease (LD) during acute illness is based on culture, polymerase chain reaction (PCR) of respiratory samples, and/or detection of Legionella antigen in urine.

The isolation of Legionella spp. by culture is considered the gold standard for diagnosing LD, but the sensitivity is low, and the urinary antigen test (UAT) has become the most performed test in diagnosing LD because of its easy performance and rapidity.

Scientists at the Ostfold Hospital Trust (Sarpsborg, Norway) investigated a long-distance outbreak of LD caused by Legionella pneumophila serogroup 1 that occurred in south-east Norway. The initial outbreak investigation without serology identified 56 laboratory-confirmed LD cases of whom 10 died. However, 116 patients with community-acquired pneumonia (CAP) might belong to the outbreak based on epidemiological investigations, but acute laboratory tests other than serology were negative or not performed.

To assess the true extent of the outbreak, they evaluated two serological assays in order to reclassify the 116 patients with indeterminate case status. The two commercial polyvalent serological L. pneumophila assays were used for evaluation of the methods and the outbreak investigation: a serogroup 1–6 immunoglobulin (Ig) G/IgM/IgA immunofluorescence assay (IFA) (Meridian Bioscience Europe; Milan, Italy) and a serogroup 1–7 enzyme-linked immunosorbent assay (ELISA) (Serion ELISA classic, Institut Virion/Serion GmbH; Würzburg, Germany) with separate levels of IgG and IgM antibodies measured in an ELISA robot (DSX Automated System, Dynex Technologies; Inc., Chantilly, VA, USA). Antibodies to the outbreak strain were determined by immunoblotting.

In the evaluation study, the sensitivity and specificity of an equal to or greater than four-fold IFA titre change was 38% and 100%, respectively, with corresponding values of 30% and 99% for seroconversion in ELISA. A single high positive IFA titre yielded sensitivity and specificity of 73% and 97%, respectively, with corresponding values of 68% and 96% for a single high immunoglobulin (Ig) G and/or IgM in ELISA.

The serological testing identified 47 more LD cases, and the outbreak thus comprised 103 cases with a case fatality rate of 10%. About the same proportion (70%) of the urinary antigen positive and negative LD cases had antibodies to the serogroup-specific lipopolysaccharide of the outbreak strain. In addition to the 103 LD cases, Legionella infection could not be verified or excluded in 32 patients based on epidemiology and/or lack of microbiological sampling.

The authors concluded that the acute-phase tests including culture, polymerase chain reaction, and urinary antigen identified less than 55% of the 103 patients in this outbreak. Serological testing thus remains an important supplement for diagnosis of LD and for determination of outbreak cases. The study was published on March 28, 2015, in the journal BMC Infectious Diseases.

Related Links:

Ostfold Hospital Trust
Meridian Bioscience Europe 
Dynex Technologies 


New
Gold Member
Syphilis Screening Test
VDRL Antigen MR
Automated Blood Typing System
IH-500 NEXT
New
FLU/RSV Test
Humasis FLU/RSV Combo
New
Human Insulin CLIA
Human Insulin CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.